Abstract
Retroviral vectors with self-inactivating (SIN) long-terminal repeats not only increase the autonomy of the internal promoter but may also reduce the risk of insertional upregulation of neighboring alleles. However, gammaretroviral as opposed to lentiviral packaging systems produce suboptimal SIN vector titers, a major limitation for their clinical use. Northern blot data revealed that low SIN titers were associated with abundant transcription of internal rather than full-length transcripts in transfected packaging cells. When using the promoter of Rous sarcoma virus or a tetracycline-inducible promoter to generate full-length transcripts, we obtained a strong enhancement in titer (up to 4 × 107 transducing units per ml of unconcentrated supernatant). Dual fluorescence vectors and Northern blots revealed that promoter competition is a rate-limiting step of SIN vector production. SIN vector stocks pseudotyped with RD114 envelope protein had high transduction efficiency in human and non-human primate cells. This study introduces a new generation of efficient gammaretroviral SIN vectors as a platform for further optimizations of retroviral vector performance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194–3198.
Zaiss AK, Son S, Chang LJ . RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209–7219.
Kraunus J, Schaumann DH, Meyer J, Modlich U, Fehse B, Brandenburg G et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Therapy 2004; 11: 1568–1578.
Ailles LE, Naldini L . HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 31–52.
Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW . Improved foamy virus vectors with minimal viral sequences. Mol Ther 2002; 6: 321–328.
Hildinger M, Abel KL, Ostertag W, Baum C . Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083–4089.
Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181–2187.
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410–2413.
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–672.
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1724.
Werner M, Kraunus J, Baum C, Brocker T . B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element. Gene Therapy 2004; 11: 992–1000.
Hope T . Improving the post-transcriptional aspects of lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 179–189.
Popa I, Harris ME, Donello JE, Hope TJ . CRM1-dependent function of a cis-acting RNA export element. Mol Cell Biol 2002; 22: 2057–2067.
Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L . Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217–222.
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463–8471.
Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391–400.
Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187–5195.
Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, Baum C . Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435–445.
Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W . Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541–7547.
Kinsella TM, Nolan GP . Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405–1413.
Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5: 242–251.
Morita S, Kojima T, Kitamura T . Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Therapy 2000; 7: 1063–1070.
Vogt B, Roscher S, Abel B, Hildinger M, Lamarre A, Baum C et al. Lack of superinfection interference in retroviral vector producer cells. Hum Gene Ther 2001; 12: 359–365.
Treisman R, Maniatis T . Simian virus 40 enhancer increases number of RNA polymerase II molecules on linked DNA. Nature 1985; 315: 73–75.
Dean DA, Dean BS, Muller S, Smith LC . Sequence requirements for plasmid nuclear import. Exp Cell Res 1999; 253: 713–722.
Galla M, Will E, Kraunus J, Chen L, Baum C . Retroviral pseudotransduction for targeted cell manipulation. Mol Cell 2004; 16: 309–315.
Bevis BJ, Glick BS . Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). Nat Biotechnol 2002; 20: 83–87.
Adhya S, Gottesman M . Promoter occlusion: transcription through a promoter may inhibit its activity. Cell 1982; 29: 939–944.
Proudfoot NJ . Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation. Nature 1986; 322: 562–565.
Emerman M, Temin HM . Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449–467.
Emerman M, Temin HM . Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res 1986; 14: 9381–9396.
Emerman M, Temin HM . Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol 1986; 6: 792–800.
Eggermont J, Proudfoot NJ . Poly(A) signals and transcriptional pause sites combine to prevent interference between RNA polymerase II promoters. EMBO J 1993; 12: 2539–2548.
Gossen M, Bujard H . Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547–5551.
Haack K, Cockrell AS, Ma H, Israeli D, Ho SN, McCown TJ et al. Transactivator and structurally optimized inducible lentiviral vectors. Mol Ther 2004; 10: 585–596.
Vigna E, Cavalieri S, Ailles L, Geuna M, Loew R, Bujard H et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 2002; 5: 252–261.
Xu K, Ma H, McCown TJ, Verma IM, Kafri T . Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3: 97–104.
Milsom MD, Fairbairn LJ . Protection and selection for gene therapy in the hematopoietic system. J Gene Med 2004; 6: 133–146.
Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R et al. Inhibition of HIV-1 entry in cells expressing Gp41-derived peptides. J Virol 2004; 78: 568–575.
Engels B, Cam H, Schüler T, Indraccolo S, Gladow M, Baum C et al. Retroviral vectors for high transgene expression in T lymphocytes. Hum Gene Ther 2003; 14: 1155–1168.
Cullen BR, Lomedico PT, Ju G . Transcriptional interference in avian retroviruses – implications for the promoter insertion model of leukaemogenesis. Nature 1984; 307: 241–245.
Greger IH, Demarchi F, Giacca M, Proudfoot NJ . Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. Nucleic Acids Res 1998; 26: 1294–1301.
Yankulov K, Blau J, Purton T, Roberts S, Bentley DL . Transcriptional elongation by RNA polymerase II is stimulated by transactivators. Cell 1994; 77: 749–759.
Neelis KJ, Dubbelman YD, Wognum AW, Thomas GR, Eaton DL, Egeland T et al. Lack of efficacy of thrombopoietin and granulocyte colony-stimulating factor after high dose total-body irradiation and autologous stem cell or bone marrow transplantation in rhesus monkeys. Exp Hematol 1997; 25: 1094–1103.
van Hennik PB, Verstegen MM, Bierhuizen MF, Limon A, Wognum AW, Cancelas JA et al. Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. Blood 1998; 92: 4013–4022.
Moritz T, Dutt P, Xiao X, Carstanjen D, Vik T, Hanenberg H et al. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 1996; 88: 855–862.
Acknowledgements
We thank L Naldini for providing the basic lentiviral construct, F-L Cosset for the RD114/TR envelope, E Will for providing M57-DAW, and C Klanke and M Id for technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (1837/Ba4) and by the Integrated Project CONSERT of the European Union (LSHB-CT-2004-005242).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)
Supplementary information
Rights and permissions
About this article
Cite this article
Schambach, A., Mueller, D., Galla, M. et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13, 1524–1533 (2006). https://doi.org/10.1038/sj.gt.3302807
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302807
Keywords
This article is cited by
-
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
Cancer Gene Therapy (2023)
-
A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML
Leukemia (2023)
-
Generation of adult hippocampal neural stem cells occurs in the early postnatal dentate gyrus and depends on cyclin D2
The EMBO Journal (2023)
-
GSK-3β orchestrates the inhibitory innervation of adult-born dentate granule cells in vivo
Cellular and Molecular Life Sciences (2023)
-
Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory
Scientific Reports (2021)